Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects

NCT03022799 is registered in ClinicalTrials.gov with Kainos Medicine Inc. as lead sponsor.

NCT NCT03022799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03022799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects
Lead sponsor
Kainos Medicine Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2016
Completion date
November 30, 2017
Enrollment
88 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease